STOCKS TELEGRAPH

Tag: NASDAQ: SUPN

  • 3 Stocks Gaining Market Attention: Cardiol Therapeutics (CRDL), Supernus Pharmaceuticals (SUPN), Prestige Consumer Healthcare (PBH)

    3 Stocks Gaining Market Attention: Cardiol Therapeutics (CRDL), Supernus Pharmaceuticals (SUPN), Prestige Consumer Healthcare (PBH)

    Amid ongoing market fluctuations, investors are paying closer attention to companies that demonstrate both adaptability and forward-looking growth strategies. In the healthcare and biotech sectors, firms that can combine scientific innovation with clear execution are increasingly being viewed as attractive opportunities in an otherwise uncertain environment.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is positioning itself as a late-stage cardiovascular biotech with a clear focus on addressing inflammation-driven diseases through targeted, non-immunosuppressive therapies. By concentrating on recurrent pericarditis, the company is targeting a well-defined patient population with limited safe long-term treatment options, creating a compelling entry point into the cardiovascular market.

    Market Momentum

    As of April 14, 2026, CRDL closed at $1.40, up 2.94%, with trading volume (764,354 shares) significantly exceeding its average of 595,566 shares—indicating renewed investor interest. With a market cap of $156.352M, the stock is trading toward the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.48 continues to reflect substantial upside potential, driven by anticipated clinical milestones.

    Clinical Focus: MAVERIC Trial

    The company’s lead candidate, CardiolRx™, is currently being evaluated in the pivotal Phase III MAVERIC trial for recurrent pericarditis. This study is designed to confirm the drug’s ability to reduce recurrence in high-risk patients, building on strong Phase II data that demonstrated rapid pain reduction and meaningful decreases in inflammation markers such as CRP. Notably, 71% of patients remained recurrence-free during the extension phase.

    Regulatory Advantage

    CardiolRx™ has been granted FDA Orphan Drug Designation, providing benefits such as potential market exclusivity, regulatory support, and pricing flexibility. These advantages enhance the commercial profile of the therapy while limiting competitive pressure in a niche indication.

    Outlook

    With strong prior data and a pivotal trial underway, Cardiol is approaching a key inflection point. Positive Phase III results could significantly re-rate the stock and establish CardiolRx™ as a leading therapy in recurrent pericarditis.

    Supernus Pharmaceuticals Inc (SUPN)

    Supernus Pharmaceuticals Inc (NASDAQ: SUPN) started the day on April 14, 2026, with a price increase of 0.32% at $50.11. During the day, the stock rose to $51.03 and sunk to $49.76. Taking a more long-term approach, SUPN posted a 52-week range of $29.16-$59.68.

    Nevertheless, stock’s Earnings Per Share (EPS) this year is -40.65%. This publicly-traded company’s shares outstanding now amounts to $57.46 million, simultaneously with a float of $54.47 million. The organization now has a market capitalization sitting at $2.89 billion.

    Prestige Consumer Healthcare Inc (PBH)

    As of April 14, 2026, Prestige Consumer Healthcare Inc (NYSE: PBH) started slowly as it slid -0.32% to $56.66. During the day, the stock rose to $57.05 and sunk to $56.20. Taking a more long-term approach, PBH posted a 52-week range of $51.24-$89.37.

    In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 9.02%. Meanwhile, its Annual Earning per share during the time was 9.02%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 0.44%. This publicly-traded company’s shares outstanding now amounts to $47.32 million, simultaneously with a float of $46.61 million. The organization now has a market capitalization sitting at $2.68 billion.

  • Stocks to Watch as Tight Election Race Creates Market Uncertainty

    Stocks to Watch as Tight Election Race Creates Market Uncertainty

    The markets are mixed this morning after results show a tight race between President Trump and Joe Biden. Markets were expecting a clear cut win by any of the two candidates. With the results expected to take longer to be released, the markets are likely to remain volatile all through the day.

    Nonetheless, there are stocks that are doing quite well pre-market and could be big winners in the day. Some of the top performers in early morning trading are as below:

    Lyft Inc [NASDAQ: LYFT]

    Lyft is up this morning after good news for ride-sharing companies in California. Uber, Instacart, DoorDash, and Lyft the main proponents of California’s Proposition 22 are well on their way to keep gig workers as independent contractors.

    So far, Associated Press has indicated that the race is favoring proponents of this proposition. Currently, about 58.2% of voters, representing about 6.3 million are supporting the Prop, while approximately 41.5%, representing about 4.5 million people are against it.

    According to the ballot measure, workers will get at least 120% of minimum wage while on the job and 30 cents compensation for engaged miles. They will also get a healthcare stipend, protection against discrimination, and on-job occupational accident insurance as well as protection from sexual harassment and liability insurance.

    Supernus Pharmaceuticals [NASDAQ: SUPN]

    Supernus Pharmaceuticals has reported its third-quarter earnings for the year 2020. In this report, SUPN reported $0.74 per share going way and above Zacks Consensus Estimate of $0.27 per share. This record is compared to $0.54 per share last year.

    This quarterly report represents an improvement of about 174.07% as compared to the same quarter the previous year. Expectations were that the company would post earnings of about $0.35 per share, but instead posted earnings of $0.65, about 85.71% surprise.

    This company has surpassed Zacks Estimates four times in a row. Supernus reported revenues of about $155.14 million for the quarter ended September 2020, exceeding Consensus Estimate by about 18.11%, as compared to last year’s revenues of $102.14 million in the same quarter.

    Digirad Corporation [NASDAQ: DRAD]

    Diversified Holding Company, Digirad Corporation that has three divisions: Healthcare, Real Estate & Investments, and Building & Construction reported today that it has entered into a stock purchase agreement planning to sell its DMS Health Technologies, Inc.

    They are planning to sell the business unit for $18.75 million. This deal is based on customary closing conditions expected to end close to the end of January 2021. DMS Health is the company’s mobile healthcare unit that deals with diagnostic imaging that includes computerized tomography, positron emission tomography as well as nuclear medicine, and magnetic resonance imaging among others.

    In 2019, this business in it posted revenue of $41.3 million which was about 40.1% of the total revenue posted by the company’s healthcare division.